德谷胰岛素与甘精胰岛素U100对西班牙裔2型糖尿病患者低血糖的影响：SWITCH 2试验结果

Chaykin Louis, Bhargava Anuj, de la Rosa Raymond, Wysham Carol H, Nørgård Troelsen Lone, Østoft Signe H, Philis-Tsimikas Athena

Meridien Research, Bradenton, FL.

Iowa Diabetes and Endocrinology Research Center, Des Moines, IA.

Clin Diabetes. 2019 Jan;37(1):73-81. doi: 10.2337/cd18-0016.

Hispanic patients with type 2 diabetes have poorer glycemic control and are at higher risk of severe diabetes complications and mortality than non-Hispanic white patients. This post hoc analysis investigated the safety and efficacy of insulin degludec versus insulin glargine 100 units/mL (glargine U100) in the Hispanic patient subpopulation from the SWITCH 2 trial. In Hispanic patients, hypoglycemia was consistently lower and nocturnal hypoglycemia was significantly lower with degludec versus glargine U100 at similar levels of glycemic control. Overall, results in Hispanic patients in SWITCH 2 were consistent with those in non-Hispanic patients.

与非西班牙裔白人患者相比，患有2型糖尿病的西班牙裔患者血糖控制较差，发生严重糖尿病并发症和死亡的风险更高。这项事后分析在SWITCH 2试验的西班牙裔患者亚组中，研究了德谷胰岛素与100单位/毫升甘精胰岛素（甘精胰岛素U100）的安全性和有效性。在西班牙裔患者中，在相似的血糖控制水平下，与甘精胰岛素U100相比，德谷胰岛素导致的低血糖持续较低，夜间低血糖显著更低。总体而言，SWITCH 2试验中西班牙裔患者的结果与非西班牙裔患者一致。